Abstract
Background: Rheumatoid arthritis is a widespread autoimmune disease and inflammation and bone destruction are two main issues in rheumatoid arthritis.
Objective: To discussing metformin effects on rheumatoid arthritis complications.
Methods: We conducted a narrative literature search including clinical trials, experimental studies on laboratory animals and cell lines. Our search covered Medline, PubMed and Google Scholar databases from 1999 until 2018. We used the terms” Metformin; Rheumatoid arthritis; Cardiovascular disease; Cancer; Osteoblastogenesis.
Discussion: Inflammatory pro-cytokines such as Interlukin-6 play important roles in T. helper 17 cell lineage differentiation. Interlukin-6 and Tumor Necrosis Factor-α activate Janus kinase receptors signal through signaling transducer and activator of transcription signaling pathway which plays important role in inflammation, bone destruction and cancer in rheumatoid arthritis patients. Interlukin-6 and Tumor Necrosis Factor-α synergistically activate signaling transducer and activator of transcription and Nuclear Factor-kβ pathways and both cytokines increase the chance of cancer development in rheumatoid arthritis patients. Metformin is AMPK activators that can suppress mTOR, STAT3 and HIF-1 so AMPK activation plays important role in suppressing inflammation and osteoclastogenesis and decreasing cancer.
Conclusion: Metformin effect on AMPK and mTOR pathways gives the capability to change Treg/Th17 balance and decrease Th17 differentiation and inflammation, osteoclastogenesis and cancers in RA patients. Metformin can be useful in protecting bones especially in first stages of RA and it can decrease inflammation, CVD and cancer in RA patients so Metformin beside DAMARs can be useful in increasing RA patients’ life quality with less harm and cost.
Keywords: Metformin, rheumatoid arthritis, cardiovascular disease, cancer, osteoblastogenesis, medicines.
Graphical Abstract
[1]
Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol 2017; 17(4): 219-32.
[2]
Guo Y, Wu Q, Ni B, et al. Tryptase is a candidate autoantigen in rheumatoid arthritis. Immunology 2014; 142(1): 67-77.
[3]
Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: An old concept with new developments. Nat Rev Rheumatol 2016; 12(6): 335-43.
[4]
Mowla K, Saki MA, Jalali MT, Zayeri ZD. How to manage rheumatoid arthritis according to classic biomarkers and polymorphisms? Front Biol 2017; 12(3): 183-91.
[5]
Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011; 112(10): 2902-9.
[6]
Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheumat Dis 2014; 73(1): 62-8.
[7]
Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73(1): 62-8.
[8]
Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 2017; 27(2): 136-40.
[9]
Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis 2015; 6: e1887.
[10]
Barra LJ, Pope JE, Hitchon C, et al. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology (Oxford) 2017; 56(5): 768-76.
[12]
Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108(8): 1167-74.
[13]
Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 2013; 110(3): 972-7.
[14]
Wang P, Ma T, Guo D, et al. Metformin induces osteoblastic differentiation of human induced pluripotent stem cell-derived mesenchymal stem cells. J Tissue Eng Regen Med 2018; 12(2): 437-46.
[15]
Mabilleau G, Chappard D, Flatt PR, Irwin N. Effects of anti-diabetic drugs on bone metabolism. Expert Rev Endocrinol Metab 2015; 10(6): 663-75.
[16]
Kim KH, Lee M-S. Autophagy--a key player in cellular and body metabolism. Nat Rev Endocrinol 2014; 10(6): 322-37.
[17]
Banerjee P, Surendran H, Chowdhury DR, Prabhakar K, Pal R. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter. J Mol Med (Berl) 2016; 94(12): 1397-409.
[18]
Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27(25): 3576-86.
[19]
Malin SK, Nightingale J, Choi SE, Chipkin SR, Braun B. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obesity (Silver Spring) 2013; 21(1): 93-100.
[20]
Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: Old or new insights? Diabetologia 2013; 56(9): 1898-906.
[21]
Calabrese LH, Rose-John S. IL-6 biology: Implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10(12): 720-7.
[22]
Sharma J, Bhar S. Devi CS. A review on Interleukins: the key manipulators in Rheumatoid Arthritis. Mod Rheumatol 2016; 1-41.
[23]
Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: Focus on preclinical RA and SLE. Nat Rev Rheumatol 2014; 10(4): 212-28.
[24]
Wei ST, Sun YH, Zong SH, Xiang YB. Serum levels of IL-6 and TNF-α May correlate with activity and severity of rheumatoid arthritis. Med Sci Monit 2015; 21: 4030-8.
[25]
Roy K, Kanwar RK, Kanwar JR. Molecular targets in arthritis and recent trends in nanotherapy. Int J Nanomedicine 2015; 10: 5407-20.
[26]
Alunno A, Manetti M, Caterbi S, et al. Altered immunoregulation in rheumatoid arthritis: The role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm 2015; 2015: 751793.
[27]
Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2015; 63(6): 435-49.
[28]
Huang G, Wang Y, Chi H. Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol 2012; 9(4): 287-95.
[29]
Barbi J, Pardoll D, Pan F. Metabolic control of the Treg/Th17 axis. Immunol Rev 2013; 252(1): 52-77.
[30]
Cook DN, Kang HS, Jetten AM. Retinoic acid-related Orphan Receptors (RORs): Regulatory functions in immunity, development, circadian rhythm, and metabolism. Nucl Receptor Res 2015; 2: 2.
[31]
Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103(9): 1345-52.
[32]
Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. BioMed Res Int 2014; 2014: 698313.
[33]
Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F. STATs: An Old Story, Yet Mesmerizing. Cell J 2015; 17(3): 395-411.
[34]
Bedoya SK, Lam B, Lau K, Larkin J III. Th17 cells in immunity and autoimmunity. Clin Dev Immunol 2013; 2013: 986789.
[35]
Park BV, Pan F. The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol 2015; 12(5): 533-42.
[36]
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017; 389(10086): 2328-37.
[37]
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7(6): 429-42.
[38]
Saki N, Abroun S, Salari F, Rahim F, Shahjahani M, Javad M-A. Molecular aspects of bone resorption in β-thalassemia major. Cell J 2015; 17(2): 193-200.
[39]
Feng W, Liu H, Luo T, Liu D, Du J, Sun J, et al. Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways. Sci Rep 2017; 27: 7.
[40]
Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44(5): 1003-12.
[41]
Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 2007; 9(1): 203.
[42]
Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30.
[43]
del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44(12): 2737-45.
[44]
Crowson CS, Liao KP, Davis JM III, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013; 166(4): 622-628.e1.
[45]
Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2016; 75(3): 560-5.
[46]
Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med 2013; 64: 249-63.
[47]
Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339(6116): 166-72.
[48]
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17(1): 212.
[49]
Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015; 74(6): 1087-93.
[50]
Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015; 36(2): 92-101.
[51]
Sen M, Johnston PA, Pollock NI, et al. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol 2017; 10(3): 129-41.
[52]
Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15(2): 79-80.
[53]
Taniguchi K, Karin M, Eds. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.Seminars in immunology 2014.
[54]
Diogo D, Okada Y, Plenge RM. Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: recent findings and challenges. Curr Opin Rheumatol 2014; 26(1): 85-92.
[55]
De Simone V, Franzè E, Ronchetti G, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 2015; 34(27): 3493-503.
[56]
Catrina AI, Joshua V, Klareskog L, Malmström V. Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev 2016; 269(1): 162-74.
[57]
Zheng W, Rao S. Knowledge-based analysis of genetic associations of rheumatoid arthritis to inform studies searching for pleiotropic genes: A literature review and network analysis. Arthritis Res Ther 2015; 17(1): 202.
[58]
Shukla SA, Rooney MS, Rajasagi M, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 2015; 33(11): 1152-8.
[59]
Son H-J, Lee J, Lee S-Y, et al. Metformin attenuates experimental
autoimmune arthritis through reciprocal regulation of Th17/Treg
balance and osteoclastogenesis. Med inflam 2014.
[60]
Lu C-H, Chung C-H, Lee C-H, et al. Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan. PLoS One 2018; 13(1): e0191242.
[61]
Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26(3): 611-7.
[62]
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13(3): 221-8.
[63]
Fan X-X, Leung EL-H, Xie Y, et al. Suppression of lipogenesis via reactive oxygen species-AMPK signaling for treating malignant and proliferative diseases. Antioxid Redox Signal 2018; 28(5): 339-57.
[64]
Jiang D, Bu Q, Zeng M, Qin S, Xia D, Peng Y. Metformin prevents proliferation of prostate cancer by regulating IGF1R/PI3K/Akt signalling in a mouse model. Biomed Res (Aligarh) 2018; 29: 416-9.
[65]
Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med 2014; 276(6): 543-59.
[66]
Turban S, Stretton C, Drouin O, et al. Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem 2012; 287(24): 20088-99.
[67]
Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol 2017; 13(5): 267-79.
[68]
Ramiscal RR, Parish IA, Lee-Young RS, et al. Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation. eLife 2015; 4: e08698.
[69]
Son HJ, Lee J, Lee SY, et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm 2014; 2014: 973986.
[70]
Yan H, Zhou HF, Hu Y, Pham CT. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J Rheum Dis Treat 2015; 1(1): 5.
[71]
Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol 2016; 12(3): 169-82.
[72]
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122(6): 253-70.
[73]
Gu Q, Gu Y, Yang H, Shi Q. Metformin Enhances Osteogenesis and Suppresses Adipogenesis of Human Chorionic Villous Mesenchymal Stem Cells. Tohoku J Exp Med 2017; 241(1): 13-9.
[74]
Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev 2015; 36(2): 194-213.
[75]
Iglesias P, Arrieta F, Piñera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf) 2011; 75(2): 184-8.
[76]
Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94(1): 45-9.
[77]
Jang WG, Kim EJ, Bae I-H, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 2011; 48(4): 885-93.
[78]
Marycz K, Tomaszewski KA, Kornicka K, et al. Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo. Oxid Med Cell Longev 2016; 2016: 9785890.
[79]
Morimoto E, Li M, Khalid AB, Krum SA, Chimge NO, Frenkel B. Glucocorticoids hijack Runx2 to stimulate Wif1 for suppression of osteoblast growth and differentiation. J Cell Physiol 2017; 232(1): 145-53.
[81]
Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone 2016; 82: 93-100.
[82]
Shao X, Cao X, Song G, Zhao Y, Shi B. Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation 2014.
[83]
Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications 2010; 24(5): 334-44.
[84]
Hegazy SK. Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab 2015; 33(2): 207-12.
[85]
Shao X, Cao X, Song G, Zhao Y, Shi B. Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation. J Diabetes Res 2014; 2014: 453940.
[86]
Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28(4): 888-94.
[87]
Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004; 53(2): 159-64.
[88]
Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; 16(10): 977-83.
[89]
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122(6): 253-70.
[90]
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014; 20(6): 953-66.
[91]
Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10(3): 143-56.
[92]
Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mole life Sci 2015; 72(12): 2337-47.
Related Books
Natural Products for the Management of Arthritic Disorders
Article Metrics
80
4